RADXRadiopharm Theranostics Ltd - ADR
RADX
Radiopharm Theranostics Ltd - ADR1,002
Mkt Cap
$54.34MVolume
19,532.0052W High
$16.2552W Low
$3.62PE Ratio
-1.56RADX Fundamentals
Price
$4.60Prev Close
$4.58Open
$4.5050D MA
$4.51Beta
0.00Avg. Volume
34,278.60EPS (Annual)
-$3.43P/B
1.57$11.85
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference
Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term clinical catalysts during a presentation at the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference.
Chief Executive Officer Riccardo Canevari described the compa...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Decrease in Short Interest
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Growth in Short Interest
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the four analysts that are presently covering...
Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) to diagnose suspected recurrent brain metastases from solid tumors...
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study
Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company's ongoing Phase IIb study of RAD101, a PET imaging tracer intended to...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Average Rating of "Buy" by Brokerages
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Short Interest Update
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of "Buy" by Brokerages
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock...
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Short Interest Up 112.6% in January
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest...
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest RADX News
ViewRadiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Decrease in Short Interest
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Growth in Short Interest
Advertisement|Remove ads.